Synairgen share price fluctuations continue! Here’s what I’d do

The Synairgen share price continues its volatile streak but investors are still confident as they snap up newly issued shares for a premium. Is it risky?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Synairgen (LSE:SNG) has yet again surprised the markets, as its share price continues to enjoy a fantastic 2020. The company issued £87m worth of new shares this week, and investors were snapping up them up with glee. By the end of Wednesday, the Synairgen share price had climbed 16% since the start of the week.

Cashing in on Covid-19

Synairgen is a pharmaceutical company specialising in respiratory drug development. Being in a prime position to help combat Covid-19, its share price has risen an astronomical 3,420% year-to-date. From January to April it had risen 1,360%. It then halved, but between July and November it’s risen a further 400%. Given the extreme volatility the share price has seen in this period, it’s clearly not a stock for the faint of heart. It doesn’t offer a dividend, and it’s listed on the notoriously erratic FTSE AIM index. 

The company’s key selling point is its drug SNG001, which has proved effective in treating the more serious side effects of Covid-19. In particular, it markedly reduced breathlessness in patients who received SNG001 compared to those receiving a placebo.

For now, the drug is yet to be licensed, and is still in phase 2 of trials. But that’s not stopped the Synairgen share price rocketing as the company has signed deals with several global partners.

Is it all downhill from here?

Investors are rightly concerned that once the pandemic is under control, Synairgen profits will take a significant hit. But hope springs eternal. Many investors are counting on it making good progress in developing and marketing other drugs in its portfolio.

With its rise to prominence now established on the world stage, there’s no doubt it could continue to grow and prosper. Within the UK it is now a part of a collaborative body of experts in life sciences and progressive research. However, pharmaceuticals is a cut-throat industry, and I think it’s those with a biotech slant that will do the best in the years to come.

Synairgen is one such stock and as such I think it could do very well indeed. Of course, this does depend on how the pandemic evolves and how it progresses its other offerings. I think the Synairgen stock remains a risky buy, particularly at an inflated price point. Nevertheless, it’s down 30% from its summer high, so there could be room for further growth yet.

An acquisition target?

In another scenario, it may get snapped up by a bigger pharma player, particularly if it has the makings of drugs in demand. Severe asthma and COPD continue to plague children and the elderly around the world. The pandemic has highlighted the need for treatments.

Just a quick glance at Synairgen’s share price fluctuations year-to-date tells me this is in no way a safe and sure-fire investment. Still, I do think it’s got a lot going for it and if I owned it, I’d be holding for now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »